TW202348136A - Viral infection inhibitor, viral infection-inhibiting particles, and viral infection-inhibiting paint - Google Patents
Viral infection inhibitor, viral infection-inhibiting particles, and viral infection-inhibiting paint Download PDFInfo
- Publication number
- TW202348136A TW202348136A TW112108497A TW112108497A TW202348136A TW 202348136 A TW202348136 A TW 202348136A TW 112108497 A TW112108497 A TW 112108497A TW 112108497 A TW112108497 A TW 112108497A TW 202348136 A TW202348136 A TW 202348136A
- Authority
- TW
- Taiwan
- Prior art keywords
- polymer compound
- viral infection
- carboxyl group
- paint
- mass
- Prior art date
Links
- 230000009385 viral infection Effects 0.000 title claims abstract description 145
- 239000003112 inhibitor Substances 0.000 title claims abstract description 79
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 63
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 57
- 239000002245 particle Substances 0.000 title claims description 45
- 239000003973 paint Substances 0.000 title abstract description 58
- 229920000642 polymer Polymers 0.000 claims abstract description 184
- 150000001875 compounds Chemical class 0.000 claims abstract description 173
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 110
- 238000000576 coating method Methods 0.000 claims abstract description 66
- 239000011248 coating agent Substances 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 230000008961 swelling Effects 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000178 monomer Substances 0.000 description 34
- 241000700605 Viruses Species 0.000 description 31
- 238000000034 method Methods 0.000 description 26
- 230000000840 anti-viral effect Effects 0.000 description 21
- 125000003118 aryl group Chemical group 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 229920002125 Sokalan® Polymers 0.000 description 16
- 239000004584 polyacrylic acid Substances 0.000 description 14
- -1 polyethylene Polymers 0.000 description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229920003002 synthetic resin Polymers 0.000 description 12
- 239000000057 synthetic resin Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 7
- 229940048053 acrylate Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 150000001451 organic peroxides Chemical class 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- 241000714201 Feline calicivirus Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000007870 radical polymerization initiator Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 2
- 229920001890 Novodur Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005577 anthracene group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000010954 inorganic particle Substances 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WRXCBRHBHGNNQA-UHFFFAOYSA-N (2,4-dichlorobenzoyl) 2,4-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC(Cl)=CC=C1C(=O)OOC(=O)C1=CC=C(Cl)C=C1Cl WRXCBRHBHGNNQA-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- KIDLQRSWTHZIAF-UHFFFAOYSA-N 1,1-bis(tert-butylperoxy)-3,3,5-trimethylhexane Chemical compound CC(C)CC(C)(C)CC(OOC(C)(C)C)OOC(C)(C)C KIDLQRSWTHZIAF-UHFFFAOYSA-N 0.000 description 1
- ROLAGNYPWIVYTG-UHFFFAOYSA-N 1,2-bis(4-methoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CC(N)C1=CC=C(OC)C=C1 ROLAGNYPWIVYTG-UHFFFAOYSA-N 0.000 description 1
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- LRZPQLZONWIQOJ-UHFFFAOYSA-N 10-(2-methylprop-2-enoyloxy)decyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCCCOC(=O)C(C)=C LRZPQLZONWIQOJ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- ODBCKCWTWALFKM-UHFFFAOYSA-N 2,5-bis(tert-butylperoxy)-2,5-dimethylhex-3-yne Chemical compound CC(C)(C)OOC(C)(C)C#CC(C)(C)OOC(C)(C)C ODBCKCWTWALFKM-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- SBYMUDUGTIKLCR-UHFFFAOYSA-N 2-chloroethenylbenzene Chemical compound ClC=CC1=CC=CC=C1 SBYMUDUGTIKLCR-UHFFFAOYSA-N 0.000 description 1
- RTEZVHMDMFEURJ-UHFFFAOYSA-N 2-methylpentan-2-yl 2,2-dimethylpropaneperoxoate Chemical compound CCCC(C)(C)OOC(=O)C(C)(C)C RTEZVHMDMFEURJ-UHFFFAOYSA-N 0.000 description 1
- BTOVVHWKPVSLBI-UHFFFAOYSA-N 2-methylprop-1-enylbenzene Chemical compound CC(C)=CC1=CC=CC=C1 BTOVVHWKPVSLBI-UHFFFAOYSA-N 0.000 description 1
- KXYAVSFOJVUIHT-UHFFFAOYSA-N 2-vinylnaphthalene Chemical compound C1=CC=CC2=CC(C=C)=CC=C21 KXYAVSFOJVUIHT-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- CEBRPXLXYCFYGU-UHFFFAOYSA-N 3-methylbut-1-enylbenzene Chemical compound CC(C)C=CC1=CC=CC=C1 CEBRPXLXYCFYGU-UHFFFAOYSA-N 0.000 description 1
- UVWVIEBLYRKAFQ-UHFFFAOYSA-N 4,4-bis(tert-butylperoxy)butyl pentanoate Chemical compound CCCCC(=O)OCCCC(OOC(C)(C)C)OOC(C)(C)C UVWVIEBLYRKAFQ-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- LQILVUYCDHSGEU-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CN1C(=O)C=CC1=O LQILVUYCDHSGEU-UHFFFAOYSA-N 0.000 description 1
- SAPGBCWOQLHKKZ-UHFFFAOYSA-N 6-(2-methylprop-2-enoyloxy)hexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCOC(=O)C(C)=C SAPGBCWOQLHKKZ-UHFFFAOYSA-N 0.000 description 1
- YJVIKVWFGPLAFS-UHFFFAOYSA-N 9-(2-methylprop-2-enoyloxy)nonyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCCOC(=O)C(C)=C YJVIKVWFGPLAFS-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 239000004641 Diallyl-phthalate Substances 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000484121 Human parvovirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- YMOONIIMQBGTDU-VOTSOKGWSA-N [(e)-2-bromoethenyl]benzene Chemical compound Br\C=C\C1=CC=CC=C1 YMOONIIMQBGTDU-VOTSOKGWSA-N 0.000 description 1
- ULQMPOIOSDXIGC-UHFFFAOYSA-N [2,2-dimethyl-3-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(C)(C)COC(=O)C(C)=C ULQMPOIOSDXIGC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N alpha-methyl toluene Natural products CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- UJMDYLWCYJJYMO-UHFFFAOYSA-N benzene-1,2,3-tricarboxylic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1C(O)=O UJMDYLWCYJJYMO-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 1
- ZDNFTNPFYCKVTB-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,4-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=C(C(=O)OCC=C)C=C1 ZDNFTNPFYCKVTB-UHFFFAOYSA-N 0.000 description 1
- MQDJYUACMFCOFT-UHFFFAOYSA-N bis[2-(1-hydroxycyclohexyl)phenyl]methanone Chemical compound C=1C=CC=C(C(=O)C=2C(=CC=CC=2)C2(O)CCCCC2)C=1C1(O)CCCCC1 MQDJYUACMFCOFT-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- YQHLDYVWEZKEOX-UHFFFAOYSA-N cumene hydroperoxide Chemical compound OOC(C)(C)C1=CC=CC=C1 YQHLDYVWEZKEOX-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005670 ethenylalkyl group Chemical group 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- HMZGPNHSPWNGEP-UHFFFAOYSA-N octadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(C)=C HMZGPNHSPWNGEP-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- GJBRNHKUVLOCEB-UHFFFAOYSA-N tert-butyl benzenecarboperoxoate Chemical compound CC(C)(C)OOC(=O)C1=CC=CC=C1 GJBRNHKUVLOCEB-UHFFFAOYSA-N 0.000 description 1
- 238000004227 thermal cracking Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
- A01N25/10—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/06—Unsaturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/02—Compositions of unspecified macromolecular compounds characterised by the presence of specified groups, e.g. terminal or pendant functional groups
- C08L101/06—Compositions of unspecified macromolecular compounds characterised by the presence of specified groups, e.g. terminal or pendant functional groups containing oxygen atoms
- C08L101/08—Carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D201/00—Coating compositions based on unspecified macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
- C09D7/65—Additives macromolecular
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Organic Chemistry (AREA)
- Pest Control & Pesticides (AREA)
- General Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Description
本發明係關於一種病毒感染抑制劑、病毒感染抑制粒子及病毒感染抑制塗料。The invention relates to a virus infection inhibitor, virus infection inhibitory particles and virus infection inhibitory paint.
近年來,除季節性流感病毒之流行外,新型冠狀病毒(COVID-19)正於全球大流行。In recent years, in addition to the prevalence of seasonal influenza viruses, the novel coronavirus (COVID-19) has become a global pandemic.
又,高病原性禽流感病毒發生變異並確認到於人類間感染,進而,對致死率極高之SARS病毒亦產生擔憂,人類對病毒之不安感日益增加。In addition, the highly pathogenic avian influenza virus has mutated and been confirmed to be infected among humans. Furthermore, concerns have arisen about the SARS virus, which has a very high fatality rate, and human beings are increasingly worried about the virus.
針對該等問題,專利文獻1中提出有一種抗病毒性合成樹脂組成物,其相對於合成樹脂100質量份包含磺酸系界面活性劑0.5質量份以上。 [先前技術文獻] [專利文獻] In order to solve these problems, Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by mass or more of a sulfonic acid-based surfactant with respect to 100 parts by mass of the synthetic resin. [Prior technical literature] [Patent Document]
[專利文獻1]日本特開2016-128395號公報[Patent Document 1] Japanese Patent Application Publication No. 2016-128395
[發明所欲解決之課題][Problem to be solved by the invention]
然而,上述抗病毒性合成樹脂組成物具有下述問題:於使其分散於塗料而使用之情形時,抗病毒性合成樹脂組成物會於塗料中成為塊(lump)狀,於將塗料塗敷於被塗敷體時在塗敷膜之表面形成條紋狀之凹凸,於所獲得之塗膜之表面形成條紋狀之凹凸。However, the above-mentioned antiviral synthetic resin composition has the following problem: when it is dispersed in a paint and used, the antiviral synthetic resin composition forms lumps in the paint, and when the paint is applied, the antiviral synthetic resin composition becomes lumpy. When applied to the object to be coated, stripe-like irregularities are formed on the surface of the coating film, and stripe-like irregularities are formed on the surface of the obtained coating film.
又,上述抗病毒性合成樹脂組成物僅於合成樹脂中含有磺酸系界面活性劑,磺酸系界面活性劑不具有充分之抗病毒性(病毒感染抑制效果),期望病毒感染抑制效果優異之病毒感染抑制劑。In addition, the above-mentioned antiviral synthetic resin composition only contains a sulfonic acid-based surfactant in the synthetic resin, and the sulfonic acid-based surfactant does not have sufficient antiviral properties (viral infection inhibitory effect). It is expected that the antiviral synthetic resin composition will have an excellent virus infection inhibitory effect. Viral infection inhibitors.
本發明提供一種病毒感染抑制劑,其可發揮優異之病毒感染抑制效果,並且於塗料中之分散性優異,可不於塗料中結塊而形成表面性優異之塗膜。 [解決課題之技術手段] The present invention provides a virus infection inhibitor that exhibits an excellent virus infection inhibitory effect, has excellent dispersibility in paint, and can form a coating film with excellent surface properties without clumping in the paint. [Technical means to solve the problem]
本發明之病毒感染抑制劑之特徵在於:包含高分子化合物,上述高分子化合物包含具有羧基或其鹽之重複單元,且上述高分子化合物之pKa1為5.5以下且具有交聯結構。The virus infection inhibitor of the present invention is characterized in that it contains a polymer compound, the polymer compound contains a repeating unit having a carboxyl group or a salt thereof, and the polymer compound has a pKa1 of 5.5 or less and has a cross-linked structure.
本發明之病毒感染抑制粒子之特徵在於包含基底粒子、及附著於上述基底粒子之表面之上述高分子化合物。The viral infection-inhibiting particles of the present invention are characterized by including base particles and the above-mentioned polymer compound attached to the surface of the base particles.
本發明之病毒感染抑制製品之特徵在於包含基材、及上述病毒感染抑制劑。 [發明之效果] The viral infection inhibitory product of the present invention is characterized by containing a base material and the above-mentioned viral infection inhibitory agent. [Effects of the invention]
本發明之病毒感染抑制劑包含高分子化合物,上述高分子化合物包含具有羧基或其鹽之重複單元,且上述高分子化合物之pKa1為5.5以下且具有交聯結構,因此即便含有於塗料中之情形時,亦可於塗料中發揮優異之分散性,良好地分散至塗料中。The viral infection inhibitor of the present invention contains a polymer compound. The polymer compound contains a repeating unit having a carboxyl group or a salt thereof. The pKa1 of the polymer compound is 5.5 or less and has a cross-linked structure. Therefore, even if it is contained in a paint When used, it can also exhibit excellent dispersibility in coatings and be well dispersed into coatings.
因此,將包含本發明之病毒感染抑制劑之塗料塗敷於被塗敷體上而獲得之塗敷膜具有優異之表面性,使該塗敷膜乾燥而獲得之塗膜具有優異之外觀性。Therefore, a coating film containing the viral infection inhibitor of the present invention is applied to an object to be coated, and the coating film obtained has excellent surface properties, and the coating film obtained by drying the coating film has excellent appearance properties.
本發明之病毒感染抑制劑包含高分子化合物作為有效成分,上述高分子化合物包含具有羧基或其鹽之重複單元,且上述高分子化合物之pKa1為5.5以下且具有交聯結構。The viral infection inhibitor of the present invention contains a polymer compound as an active ingredient. The polymer compound contains a repeating unit having a carboxyl group or a salt thereof, and the polymer compound has a pKa1 of 5.5 or less and has a cross-linked structure.
本發明之病毒感染抑制劑含有高分子化合物作為有效成分,上述高分子化合物包含具有羧基或其鹽之重複單元。The viral infection inhibitor of the present invention contains a polymer compound containing a repeating unit having a carboxyl group or a salt thereof as an active ingredient.
於病毒感染抑制劑中,包含具有羧基或其鹽之重複單元且pKa1為5.5以下並具有交聯結構之高分子化合物之含量較佳為80質量%以上,更佳為85質量%以上,更佳為90質量%以上,更佳為95質量%以上,更佳為99質量%以上,更佳為100質量%。In the viral infection inhibitor, the content of the polymer compound containing a repeating unit having a carboxyl group or a salt thereof and having a pKa1 of 5.5 or less and a cross-linked structure is preferably 80 mass% or more, more preferably 85 mass% or more, even more preferably It is 90 mass % or more, more preferably 95 mass % or more, more preferably 99 mass % or more, more preferably 100 mass %.
於病毒感染抑制劑中,包含具有羧基或其鹽之重複單元且pKa1為5.5以下並具有交聯結構之高分子化合物之含量於有效成分中較佳為80質量%以上,更佳為85質量%以上,更佳為90質量%以上,更佳為95質量%以上,更佳為99質量%以上,更佳為100質量%。In the viral infection inhibitor, the content of the polymer compound containing a repeating unit having a carboxyl group or a salt thereof and having a pKa1 of 5.5 or less and a cross-linked structure is preferably 80 mass % or more, more preferably 85 mass % in the active ingredient. Above, more preferably 90 mass% or more, more preferably 95 mass% or more, more preferably 99 mass% or more, still more preferably 100 mass%.
高分子化合物於分子中具有羧基(-COOH)或其鹽。高分子化合物因包含羧基或其鹽之結構部分而發揮病毒感染抑制效果。高分子化合物尤其對具有套膜(envelope)之病毒具有優異之病毒感染抑制效果。The polymer compound has a carboxyl group (-COOH) or its salt in the molecule. The polymer compound exhibits a virus infection inhibitory effect because it contains a structural moiety of a carboxyl group or a salt thereof. Polymer compounds have excellent viral infection inhibitory effects especially on viruses with envelopes.
高分子化合物所包含之羧基之鹽並無特別限定,例如可例舉:鈉鹽(-COONa)、鈣鹽[(-COO -) 2Ca 2+]、銨鹽(-COO -NH 4 +)、鎂鹽[(-COO -) 2Mg 2+]、鋇鹽[(-COO -) 2Ba 2+]等。 The salt of the carboxyl group contained in the polymer compound is not particularly limited, and examples include sodium salt (-COONa), calcium salt [(-COO - ) 2 Ca 2+ ], ammonium salt (-COO - NH 4 + ) , magnesium salt [(-COO - ) 2 Mg 2+ ], barium salt [(-COO - ) 2 Ba 2+ ], etc.
再者,病毒感染抑制效果係指使病毒對細胞之感染力喪失或降低、或者即便感染亦無法於細胞中增殖之效果。作為此種確認病毒有無感染性之方法,例如若為纖維製品,則可例舉ISO18184或JIS L1922,若為纖維製品以外之塑膠或非多孔質表面之製品,則可例舉ISO21702。此外還可例舉如記載於「醫藥科病毒學」(1990年4月初版發行)之溶菌斑(plaque)法或紅血球凝集效價(HAU)測定法等。In addition, the virus infection inhibitory effect refers to the effect of losing or reducing the infectivity of the virus to cells, or preventing the virus from proliferating in the cells even if it is infected. As a method for confirming whether the virus is infective, for example, if it is a fiber product, ISO18184 or JIS L1922 can be cited, and if it is a plastic or non-porous surface product other than a fiber product, ISO21702 can be cited. Other examples include the plaque method and the erythrocyte agglutination titer (HAU) measurement method described in "Pharmaceutical Virology" (first edition published in April 1990).
病毒感染抑制劑之病毒感染抑制效果例如可按下述要領進行測定。將病毒感染抑制劑、及紫外線硬化型丙烯酸系塗料97質量份混合而製作病毒感染抑制塗料。使用線棒塗佈器(wire bar coater)#8,將病毒感染抑制塗料於聚乙烯膜上塗敷成厚度18 μm而形成塗敷層。The viral infection inhibitory effect of the viral infection inhibitor can be measured, for example, according to the following method. A viral infection inhibitor and 97 parts by mass of an ultraviolet curable acrylic paint were mixed to prepare a virus infection inhibiting paint. Using a wire bar coater #8, apply the viral infection-inhibiting paint on the polyethylene film to a thickness of 18 μm to form a coating layer.
於25℃向塗敷層照射波長365 nm之紫外線至累計光量達到500 mJ/cm 2,使紫外線硬化型丙烯酸系塗料硬化,形成厚度為18 μm之塗膜。 The coating layer is irradiated with ultraviolet light with a wavelength of 365 nm at 25°C until the cumulative light intensity reaches 500 mJ/cm 2 to harden the ultraviolet curable acrylic paint to form a coating film with a thickness of 18 μm.
對塗膜切出一邊為5.0 cm之平面正方形狀,藉此製作試片。對於所獲得之試片塗膜之表面,使用一邊為10 cm之平面正方形狀之不織布,使不織布往返10次而進行擦拭,從而製成試驗塗膜。Cut out a flat square shape with a side of 5.0 cm from the coating film to prepare a test piece. The surface of the obtained test piece coating film was wiped with a flat square-shaped non-woven fabric with a side of 10 cm, and the non-woven fabric was moved back and forth 10 times to prepare a test coating film.
依據ISO21702,對所獲得之試驗塗膜進行抗病毒試驗。對反應後之病毒懸濁液,藉由溶菌斑法算出試驗塗膜之病毒感染效價(常用對數值)(PFU/cm 2)。 According to ISO21702, the antiviral test was conducted on the obtained test coating film. For the virus suspension after the reaction, calculate the virus infection titer (commonly used logarithmic value) (PFU/cm 2 ) of the test coating through the plaque lysis method.
除不含病毒感染抑制劑以外,按與上文相同之要領製作空白塗膜,基於該空白塗膜,按與上文相同之要領算出病毒感染效價(常用對數值)(PFU/cm 2)。 Except that it does not contain viral infection inhibitors, make a blank coating film according to the same method as above. Based on the blank coating film, calculate the virus infection titer (common logarithmic value) (PFU/cm 2 ) according to the same method as above. .
自空白塗膜之病毒感染效價減去試驗塗膜之病毒感染效價,藉此算出抗病毒活性值。The antiviral activity value was calculated by subtracting the viral infection titer of the test coating from the viral infection titer of the blank coating.
關於病毒感染抑制劑,自依據ISO21702進行之抗病毒試驗之反應開始經過10分鐘後之抗病毒活性值較佳為2.0以上。關於病毒感染抑制劑,自依據ISO21702進行之抗病毒試驗之反應開始經過24小時後之抗病毒活性值較佳為2.0以上。無論要評價之病毒之種類為何,較佳為對至少一種病毒,抗病毒活性值達到2.0以上。Regarding the viral infection inhibitor, the antiviral activity value 10 minutes after the reaction in the antiviral test based on ISO21702 is preferably 2.0 or more. Regarding viral infection inhibitors, the antiviral activity value 24 hours after the reaction in the antiviral test conducted in accordance with ISO21702 is preferably 2.0 or more. Regardless of the types of viruses to be evaluated, it is preferred that the antiviral activity value for at least one virus reaches 2.0 or above.
高分子化合物之pKa1為5.5以下,較佳為5.0以下,更佳為4.7以下。若高分子化合物之pKa1為5.5以下,則病毒感染抑制劑之病毒感染抑制效果提高。於高分子化合物為多元酸之情形時,高分子化合物多階段地進行游離,pKa1係指基於第一階段之游離常數算出之pKa。此處,於電解質HA游離成H +及A -並取得游離平衡(1)時,酸解離常數Ka係以式(2)來定義,pKa係以酸解離常數Ka之反數之常用對數(3)來定義。 The pKa1 of the polymer compound is 5.5 or less, preferably 5.0 or less, more preferably 4.7 or less. If the pKa1 of the polymer compound is 5.5 or less, the virus infection inhibitory effect of the virus infection inhibitor is improved. When the polymer compound is a polybasic acid, the polymer compound dissociates in multiple stages, and pKa1 refers to the pKa calculated based on the dissociation constant of the first stage. Here, when the electrolyte HA dissociates into H + and A - and achieves dissociation equilibrium (1), the acid dissociation constant Ka is defined by formula (2), and pKa is the common logarithm of the inverse of the acid dissociation constant Ka (3 ) to define.
高分子化合物之pKa1係指藉由滴定所測得之值。具體而言,可使用高分子化合物及氫氧化鈉於25℃進行滴定,測定半當量點(滴下中和結束之量之一半之時點)時於25℃之pH,藉此求出pKa1。The pKa1 of a polymer compound refers to the value measured by titration. Specifically, pKa1 can be determined by titrating a polymer compound and sodium hydroxide at 25°C and measuring the pH at 25°C at the half-equivalence point (the point at which half the amount of neutralization is dropped).
再者,於高分子化合物中包含羧基之鹽時,高分子化合物之pKa1係設為:將羧基之鹽轉化為羧基後,利用上述方法所測得之高分子化合物之pKa1。作為將羧基之鹽轉化為羧基之方法例如可例舉下述方法,即,將高分子化合物混合於1 mol%鹽酸水溶液,並將高分子化合物所包含之所有羧基之鹽轉化為羧基,其後藉由冷凍乾燥等通用之要領將鹽酸及水除去。Furthermore, when the polymer compound contains a salt of a carboxyl group, the pKa1 of the polymer compound is the pKa1 of the polymer compound measured by the above method after converting the salt of the carboxyl group into a carboxyl group. An example of a method for converting salts of carboxyl groups into carboxyl groups is a method in which a polymer compound is mixed with a 1 mol % aqueous hydrochloric acid solution, and all salts of carboxyl groups contained in the polymer compound are converted into carboxyl groups, and then Hydrochloric acid and water are removed by common methods such as freeze-drying.
高分子化合物之重量平均分子量為3000以上,較佳為5000以上,更佳為10000以上,更佳為100000以上。若高分子化合物之重量平均分子量為3000以上,則每一分子之高分子化合物與病毒之吸附點增大,高分子化合物與病毒之相互作用變強,可提高病毒感染抑制劑之病毒感染抑制效果。The weight average molecular weight of the polymer compound is 3,000 or more, preferably 5,000 or more, more preferably 10,000 or more, more preferably 100,000 or more. If the weight average molecular weight of the polymer compound is more than 3000, the adsorption point between each molecule of the polymer compound and the virus will increase, and the interaction between the polymer compound and the virus will become stronger, which can improve the virus infection inhibitory effect of the virus infection inhibitor. .
高分子化合物所包含之聚合物之重量平均分子量較佳為1000000以下,更佳為900000以下,更佳為800000以下,更佳為500000以下。若高分子化合物之重量平均分子量為1000000以下,則高分子化合物於塗料中之分散性提高,結果成為高分子化合物與病毒容易相互作用之形態,病毒感染抑制劑之病毒感染抑制效果提高。The weight average molecular weight of the polymer contained in the polymer compound is preferably 1,000,000 or less, more preferably 900,000 or less, more preferably 800,000 or less, still more preferably 500,000 or less. If the weight average molecular weight of the polymer compound is 1,000,000 or less, the dispersibility of the polymer compound in the paint is improved, resulting in a form in which the polymer compound and viruses easily interact, and the virus infection inhibitory effect of the virus infection inhibitor is improved.
再者,於本發明中,聚合物之重量平均分子量係藉由GPC(凝膠滲透層析)法所測得之經聚苯乙烯換算之值。Furthermore, in the present invention, the weight average molecular weight of the polymer is a polystyrene-converted value measured by GPC (gel permeation chromatography) method.
例如,可藉由下述測定裝置及測定條件進行測定。 凝膠滲透層析儀:Waters公司製造 商品名「2690 Separations Model」 管柱:昭和電工公司製造 商品名「GPC KF-806L」 檢測器:示差折射計 樣品流量:1 mL/min 管柱溫度:40℃ 溶離液:THF For example, the measurement can be performed with the following measurement device and measurement conditions. Gel permeation chromatography: Manufactured by Waters Co., Ltd. Trade name "2690 Separations Model" Pipe string: Manufactured by Showa Denko Co., Ltd. Trade name "GPC KF-806L" Detector: Differential Refractometer Sample flow: 1 mL/min Tube string temperature: 40℃ Eluent: THF
高分子化合物於25℃之pH較佳為2以上,更佳為3以上,更佳為4以上。高分子化合物於25℃之pH更佳為4.5以下。若高分子化合物之pH為2以上,則病毒感染抑制劑之病毒感染抑制效果提高。若高分子化合物之pH為4.5以下,則對不具有套膜之病毒之病毒感染抑制效果提高。再者,高分子化合物之pH係指將高分子化合物0.5 g加入純化水99.5 g中並均勻混合而成之混合液於25℃之pH值。關於混合液,可將高分子化合物之總量溶解於純化水或將高分子化合物之一部分溶解於純化水而成為飽和水溶液。The pH of the polymer compound at 25°C is preferably 2 or more, more preferably 3 or more, and more preferably 4 or more. The pH of the polymer compound at 25°C is preferably below 4.5. If the pH of the polymer compound is 2 or more, the virus infection inhibitory effect of the virus infection inhibitor will be improved. If the pH of the polymer compound is 4.5 or less, the virus infection inhibitory effect on viruses that do not have a mantle is improved. Furthermore, the pH of a polymer compound refers to the pH value at 25°C of a mixed solution obtained by adding 0.5 g of the polymer compound to 99.5 g of purified water and uniformly mixing. Regarding the mixed liquid, the total amount of the polymer compound can be dissolved in purified water or a part of the polymer compound can be dissolved in purified water to form a saturated aqueous solution.
高分子化合物含有具有羧基或其鹽之重複單元,作為該重複單元可例舉含有羧基或其鹽之含羧基衍生物之單體單元。高分子化合物可為含羧基衍生物之單體之均聚物,亦可為含羧基衍生物之單體與可與其共聚之單體之共聚物。The polymer compound contains a repeating unit having a carboxyl group or a salt thereof. Examples of the repeating unit include a monomer unit containing a carboxyl group-containing derivative of a carboxyl group or a salt thereof. The polymer compound may be a homopolymer of a monomer containing a carboxyl derivative, or a copolymer of a monomer containing a carboxyl derivative and a monomer copolymerizable therewith.
作為含羧基衍生物之單體並無特別限定,例如可例舉:丙烯酸、甲基丙烯酸、(甲基)丙烯酸β-羧基乙酯、(甲基)丙烯酸5-羧基戊酯、琥珀酸單(甲基)丙烯醯氧基乙酯、ω-羧基聚己內酯單(甲基)丙烯酸酯、丁烯酸、順丁烯二酸、反丁烯二酸、伊康酸、檸康酸、羧基甜菜鹼型單體或其等之鹽等,較佳為丙烯酸、甲基丙烯酸、丙烯酸鈉、甲基丙烯酸鈉。再者,含羧基衍生物之單體可單獨使用亦可將兩種以上併用。The monomer of the carboxyl group-containing derivative is not particularly limited, and examples thereof include: acrylic acid, methacrylic acid, (meth)acrylic acid β-carboxyethyl ester, (meth)acrylic acid 5-carboxypentyl ester, succinic acid mono( Methacryloyloxyethyl ester, ω-carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, carboxyl Betaine type monomers or salts thereof are preferably acrylic acid, methacrylic acid, sodium acrylate, or sodium methacrylate. In addition, the carboxyl derivative-containing monomer may be used alone or in combination of two or more types.
作為可與含羧基衍生物之單體共聚之單體並無特別限定,例如可例舉:丙烯酸烷基酯、甲基丙烯酸烷基酯、乙烯基烷基醚、乙酸乙烯酯、乙烯、丙烯、丁烯、丁二烯、二異丁烯、氯乙烯、偏二氯乙烯、2-乙烯基萘、苯乙烯、丙烯腈、丙烯醯胺、甲基丙烯醯胺、二丙酮丙烯醯胺、乙烯基甲苯、乙烯基吡啶等。再者,可與含羧基衍生物之單體共聚之單體可單獨使用亦可將兩種以上併用。The monomer copolymerizable with the carboxyl derivative-containing monomer is not particularly limited, and examples thereof include: alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, Butene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene, Vinylpyridine etc. Furthermore, the monomer copolymerizable with the carboxyl derivative-containing monomer may be used alone or in combination of two or more types.
高分子化合物中之含羧基衍生物之單體單元之含量較佳為80質量%以上,更佳為85質量%以上,更佳為90質量%以上。高分子化合物中之含羧基衍生物之單體單元之含量較佳為99質量%以下,更佳為97質量%以下,更佳為95質量%以下。若高分子化合物中之含羧基衍生物之單體單元之含量為80質量%以上,則病毒感染抑制劑之病毒感染抑制效果提高。若高分子化合物中之含羧基衍生物之單體單元之含量為99質量%以下,則塗料中之高分子化合物之分散性提高,可減少病毒感染抑制劑於塗料中結塊之情況,可形成表面性優異之塗膜,並且成為高分子化合物與病毒容易相互作用之形態,病毒感染抑制劑之病毒感染抑制效果提高。The content of the carboxyl derivative-containing monomer unit in the polymer compound is preferably 80 mass% or more, more preferably 85 mass% or more, and more preferably 90 mass% or more. The content of the carboxyl derivative-containing monomer unit in the polymer compound is preferably 99 mass% or less, more preferably 97 mass% or less, and more preferably 95 mass% or less. If the content of the carboxyl derivative-containing monomer unit in the polymer compound is 80% by mass or more, the virus infection inhibitory effect of the virus infection inhibitor is improved. If the content of monomer units containing carboxyl derivatives in the polymer compound is less than 99% by mass, the dispersibility of the polymer compound in the paint can be improved, which can reduce the caking of virus infection inhibitors in the paint and can form The coating film has excellent surface properties and forms a form in which polymer compounds and viruses can easily interact, thereby improving the virus infection inhibitory effect of the virus infection inhibitor.
高分子化合物使用通用之聚合方法進行聚合即可。例如,可藉由使含有含羧基衍生物之單體之單體組成物於通用之自由基聚合起始劑之存在下聚合而獲得高分子化合物。再者,作為自由基聚合起始劑可例舉:1-羥基環己烷-1-基苯基酮、過氧化特戊酸第三己酯(t-hexyl peroxypivalate)、過氧化苯甲醯、偶氮二異丁腈等熱裂解型自由基聚合起始劑等。Polymer compounds can be polymerized using general polymerization methods. For example, a polymer compound can be obtained by polymerizing a monomer composition containing a carboxyl derivative-containing monomer in the presence of a general-purpose radical polymerization initiator. Furthermore, examples of the radical polymerization initiator include: 1-hydroxycyclohexan-1-ylphenyl ketone, t-hexyl peroxypivalate, benzoyl peroxide, Thermal cracking free radical polymerization initiators such as azobisisobutyronitrile, etc.
高分子化合物較佳為於分子中不含芳香族環。若高分子化合物不含芳香族環,則高分子化合物之體積減小,故而包含羧基或其鹽之分子結構部分可高效率地與病毒相互作用,發揮優異之病毒感染抑制效果。The polymer compound preferably does not contain aromatic rings in the molecule. If the polymer compound does not contain an aromatic ring, the volume of the polymer compound is reduced, so the molecular structure part containing a carboxyl group or its salt can interact with viruses efficiently and exert an excellent virus infection inhibitory effect.
芳香族環除單環狀之芳香族環外,亦包含單環狀之芳香族環複合並縮合而成之縮合芳香族環。芳香族環並無特別限定,例如可例舉苯環、萘環、蒽環、聯苯、苯氧基苯基等。芳香族環中,鍵結於直接構成芳香族環及縮合芳香族環之碳原子之氫原子中之任一個或複數個氫原子被奪去,並藉由共價鍵與其他原子鍵結。In addition to monocyclic aromatic rings, aromatic rings also include condensed aromatic rings in which monocyclic aromatic rings are compounded and condensed. The aromatic ring is not particularly limited, and examples thereof include benzene ring, naphthalene ring, anthracene ring, biphenyl, phenoxyphenyl group, and the like. In an aromatic ring, any one or more of the hydrogen atoms bonded to the carbon atoms directly constituting the aromatic ring and the condensed aromatic ring are taken away and bonded to other atoms through covalent bonds.
高分子化合物中之羧基及羧基之鹽之總含量較佳為5 mmol/g以上,較佳為7 mmol/g以上,較佳為9 mmol/g以上,較佳為11 mmol/g以上,較佳為13 mmol/g以上。高分子化合物中之羧基及羧基之鹽之總含量較佳為20 mmol/g以下,較佳為18 mmol/g以下,較佳為17 mmol/g以下,較佳為16 mmol/g以下。若高分子化合物中之羧基及羧基之鹽之總含量為5 mmol/g以上,則病毒感染抑制劑之病毒感染抑制效果提高。若高分子化合物中之羧基及羧基之鹽之總含量為20 mmol/g以下,則高分子化合物之塗料中之病毒感染抑制劑之分散性提高,病毒感染抑制劑不易於塗料中結塊,可形成表面性優異之塗膜,並且成為高分子化合物與病毒容易相互作用之形態,病毒感染抑制劑之病毒感染抑制效果提高。The total content of the carboxyl group and the salt of the carboxyl group in the polymer compound is preferably 5 mmol/g or more, preferably 7 mmol/g or more, preferably 9 mmol/g or more, preferably 11 mmol/g or more, and preferably 11 mmol/g or more. Preferably, it is above 13 mmol/g. The total content of the carboxyl group and the salt of the carboxyl group in the polymer compound is preferably 20 mmol/g or less, preferably 18 mmol/g or less, preferably 17 mmol/g or less, and preferably 16 mmol/g or less. If the total content of the carboxyl group and the salt of the carboxyl group in the polymer compound is 5 mmol/g or more, the virus infection inhibitory effect of the virus infection inhibitor will be improved. If the total content of the carboxyl group and the salt of the carboxyl group in the polymer compound is less than 20 mmol/g, the dispersibility of the virus infection inhibitor in the paint of the polymer compound will be improved, and the virus infection inhibitor will not be easy to agglomerate in the paint, and can It forms a coating film with excellent surface properties and becomes a form in which polymer compounds and viruses can easily interact, thereby improving the virus infection inhibitory effect of the virus infection inhibitor.
於高分子化合物中,藉由調整凝膠分率、以及羧基及羧基之鹽之總含量兩者,可使羧基及羧基之鹽朝外側有效地配向,可提高病毒感染抑制劑之病毒感染抑制效果。In polymer compounds, by adjusting both the gel fraction and the total content of the carboxyl group and the salt of the carboxyl group, the carboxyl group and the salt of the carboxyl group can be effectively aligned toward the outside, thereby improving the virus infection inhibitory effect of the virus infection inhibitor. .
再者,高分子化合物中之羧基及羧基之鹽之總含量係指藉由滴定所測得之值。具體而言,準確稱量已乾燥之高分子化合物約1 g(A g),並向高分子化合物中加入200 mL之純化水,其後使用0.1 mol/L氫氧化鈉水溶液於25℃進行滴定,求出至半當量點(滴下中和結束之量之一半之時點)為止所消耗之氫氧化鈉水溶液消耗量(B mL),利用下式算出高分子化合物中之羧基之含量(mmol/g)。再者,於高分子化合物含有羧基之鹽之情形時,將高分子化合物混合至1 mol%鹽酸水溶液中,並將高分子化合物所包含之所有羧基之鹽轉化為羧基,其後對高分子化合物按上述要領測定羧基之含量,將所獲得之羧基之含量(mmol/g)設為羧基及羧基之鹽之總含量(mmol/g)。 羧基之含量(mmol/g)=0.1×A/B In addition, the total content of the carboxyl group and the salt of the carboxyl group in the polymer compound refers to the value measured by titration. Specifically, accurately weigh about 1 g (A g) of the dried polymer compound, add 200 mL of purified water to the polymer compound, and then titrate with 0.1 mol/L sodium hydroxide aqueous solution at 25°C. , calculate the consumption of sodium hydroxide aqueous solution (B mL) up to the half-equivalence point (the point at which half of the amount of dripping and neutralization is completed), and calculate the carboxyl group content (mmol/g) in the polymer compound using the following formula ). Furthermore, when the polymer compound contains a salt of a carboxyl group, the polymer compound is mixed into a 1 mol% hydrochloric acid aqueous solution, and all the salts of the carboxyl groups contained in the polymer compound are converted into carboxyl groups, and then the polymer compound is Determine the carboxyl group content according to the above method, and set the obtained carboxyl group content (mmol/g) as the total content of the carboxyl group and the salt of the carboxyl group (mmol/g). Carboxyl content (mmol/g) = 0.1×A/B
病毒感染抑制劑之有效成分即高分子化合物具有交聯結構。藉由高分子化合物具有交聯結構,於使病毒感染抑制劑分散於塗料中時可減少高分子化合物吸收塗料而膨潤之情況,減少高分子化合物之膨潤所引起的塗料中之分散性之降低,高分子化合物於塗料中具有優異之分散性。因此,將含有病毒感染抑制劑之塗料塗敷於被塗敷體上而獲得之塗敷膜中不會形成條紋狀之凹凸,所獲得之塗膜之表面性優異,具有優異之外觀。The active ingredients of viral infection inhibitors, namely polymer compounds, have a cross-linked structure. Because the polymer compound has a cross-linked structure, when the virus infection inhibitor is dispersed in the paint, it can reduce the situation where the polymer compound absorbs the paint and swells, and reduces the decrease in dispersion in the paint caused by the swelling of the polymer compound. Polymer compounds have excellent dispersibility in coatings. Therefore, stripe-like unevenness will not be formed in the coating film obtained by applying the coating material containing the virus infection inhibitor to the object to be coated, and the coating film obtained will have excellent surface properties and excellent appearance.
向高分子化合物導入交聯結構之方法並無特別限定,例如可例舉:向高分子化合物添加有機過氧化物並加熱至有機過氧化物之分解溫度以上而使高分子化合物交聯之方法等。The method of introducing a cross-linked structure into the polymer compound is not particularly limited. For example, a method of adding an organic peroxide to the polymer compound and heating the polymer compound to a temperature higher than the decomposition temperature of the organic peroxide to cross-link the polymer compound, etc. .
作為有機過氧化物並無特別限定,例如可例舉:過氧化特戊酸第三己酯、過氧化苯甲醯、過氧化2,4-二氯苯甲醯、過氧苯甲酸第三丁酯、氫過氧化異丙苯(cumyl hydroperoxide)、第三丁基過氧化氫、1,1-二(第三丁基過氧基)-3,3,5-三甲基己烷、4,4-二(第三丁基過氧基)戊酸正丁酯、α,α'-雙(第三丁基過氧基異丙基)苯、2,5-二甲基-2,5-二(第三丁基過氧基)己炔-3、第三丁基過氧化異丙苯等。The organic peroxide is not particularly limited, and examples thereof include: tert-hexyl pivalate peroxide, benzoyl peroxide, 2,4-dichlorobenzoyl peroxide, and tert-butyl peroxybenzoate. Ester, cumyl hydroperoxide, tert-butyl hydroperoxide, 1,1-di(tert-butylperoxy)-3,3,5-trimethylhexane, 4, 4-Di(tert-butylperoxy)n-butyl valerate, α,α'-bis(tert-butylperoxyisopropyl)benzene, 2,5-dimethyl-2,5- Di(tert-butylperoxy)hexyne-3, tert-butylperoxycumyl, etc.
對高分子化合物導入交聯結構之程度可藉由調整添加至高分子化合物中之有機過氧化物之量進行控制。添加至高分子化合物中之有機過氧化物之量相對於高分子化合物100質量份較佳為0.01~10質量份,更佳為0.1~5質量份。The degree of introducing a cross-linked structure into the polymer compound can be controlled by adjusting the amount of organic peroxide added to the polymer compound. The amount of the organic peroxide added to the polymer compound is preferably 0.01 to 10 parts by mass, more preferably 0.1 to 5 parts by mass relative to 100 parts by mass of the polymer compound.
於藉由有機過氧化物使高分子化合物交聯時亦可使用交聯助劑。作為交聯助劑例如可例舉:二乙烯苯、三羥甲基丙烷三甲基丙烯酸酯、1,9-壬二醇二甲基丙烯酸酯、1,10-癸二醇二甲基丙烯酸酯、苯三甲酸三烯丙酯、異氰尿酸三烯丙酯、乙基乙烯苯、新戊二醇二甲基丙烯酸酯、1,2,4-苯三羧酸三烯丙酯、1,6-己二醇二甲基丙烯酸酯、甲基丙烯酸月桂酯、甲基丙烯酸硬脂酯、鄰苯二甲酸二烯丙酯、對苯二甲酸二烯丙酯、間苯二甲酸二烯丙酯等。Cross-linking assistants can also be used when cross-linking polymer compounds with organic peroxides. Examples of crosslinking aids include divinylbenzene, trimethylolpropane trimethacrylate, 1,9-nonanediol dimethacrylate, and 1,10-decanediol dimethacrylate. , triallyl benzenetricarboxylate, triallyl isocyanurate, ethyl vinylbenzene, neopentyl glycol dimethacrylate, triallyl 1,2,4-benzenetricarboxylate, 1,6 -Hexylene glycol dimethacrylate, lauryl methacrylate, stearyl methacrylate, diallyl phthalate, diallyl terephthalate, diallyl isophthalate, etc. .
對高分子化合物導入交聯結構之程度可藉由調整添加至高分子化合物中之交聯助劑之量進行控制。添加至高分子化合物之交聯助劑之量相對於高分子化合物100質量份較佳為0.01質量份以上,更佳為0.1質量份以上。添加至高分子化合物之交聯助劑之量相對於高分子化合物100質量份較佳為10質量份以下,更佳為5質量份以下。The degree of introducing a cross-linked structure into the polymer compound can be controlled by adjusting the amount of cross-linking auxiliary added to the polymer compound. The amount of the cross-linking auxiliary added to the polymer compound is preferably 0.01 parts by mass or more, more preferably 0.1 parts by mass or more based on 100 parts by mass of the polymer compound. The amount of the cross-linking auxiliary added to the polymer compound is preferably 10 parts by mass or less, more preferably 5 parts by mass or less based on 100 parts by mass of the polymer compound.
高分子化合物之凝膠分率較佳為65質量%以上,更佳為70質量%以上,更佳為75質量%以上,更佳為80質量%以上。高分子化合物之凝膠分率較佳為99質量%以下,更佳為98質量%以下,更佳為95質量%以下,更佳為90質量%以下,更佳為85質量%以下。若高分子化合物之凝膠分率為65質量%以上,則於使病毒感染抑制劑分散於塗料中時,可減少高分子化合物吸收塗料而膨潤之情況,減少高分子化合物之膨潤引起的塗料中之高分子化合物之分散性之降低,高分子化合物於塗料中具有優異之分散性,可形成具有優異之表面性之塗膜。若高分子化合物之凝膠分率為99質量%以下,則可使羧基及羧基之鹽朝外側有效地配向,可提高病毒感染抑制劑之病毒感染抑制效果。The gel fraction of the polymer compound is preferably 65 mass% or more, more preferably 70 mass% or more, more preferably 75 mass% or more, and more preferably 80 mass% or more. The gel fraction of the polymer compound is preferably 99 mass% or less, more preferably 98 mass% or less, more preferably 95 mass% or less, more preferably 90 mass% or less, still more preferably 85 mass% or less. If the gel fraction of the polymer compound is 65% by mass or more, when the viral infection inhibitor is dispersed in the paint, the polymer compound absorbs the paint and swells, thereby reducing the risk of the polymer compound swelling in the paint. The dispersion of the polymer compound is reduced. The polymer compound has excellent dispersion in the coating and can form a coating film with excellent surface properties. If the gel fraction of the polymer compound is 99% by mass or less, the carboxyl group and the salt of the carboxyl group can be effectively aligned outward, thereby improving the virus infection inhibitory effect of the virus infection inhibitor.
再者,高分子化合物之凝膠分率係指按下述要領所測得之值。稱量高分子化合物A g,將其於60℃之純化水中浸漬24小時並利用200目之金屬絲網過濾不溶解成分,對金屬絲網上之殘渣進行真空乾燥並測定乾燥殘渣之重量(B g),藉由下式算出凝膠分率。 高分子化合物之凝膠分率(質量%)=(B/A)×100 In addition, the gel fraction of a polymer compound refers to a value measured according to the following method. Weigh the polymer compound A g, immerse it in purified water at 60°C for 24 hours, filter the insoluble components using a 200-mesh wire mesh, vacuum dry the residue on the wire mesh, and measure the weight of the dried residue (B g), calculate the gel fraction by the following formula. Gel fraction of polymer compound (mass %) = (B/A) × 100
高分子化合物於水中之膨潤率較佳為800%以上,更佳為850%以上,更佳為1000%以上,更佳為1200%以上,更佳為1300%以上。高分子化合物於水中之膨潤率較佳為3000%以下,更佳為2900%以下,更佳為2800%以下,更佳為2700%以下,更佳為2600%以下。病毒存在於唾液等包含水分之液體中之情況較多,若高分子化合物於水中之膨潤率為800%以上,則高分子化合物會因接觸包含病毒及水分之液體而有效地膨潤,從而使表面積增加,成為容易進行與病毒之相互作用之形態,病毒感染抑制劑之病毒感染抑制效果提高。若高分子化合物於水中之膨潤率為3000%以下,則可減小使用中之高分子化合物之形狀變化,可減少病毒感染抑制劑自塗膜中之脫落,穩定地維持塗膜所具有之優異之病毒感染抑制效果。The swelling rate of the polymer compound in water is preferably more than 800%, more preferably more than 850%, more preferably more than 1000%, more preferably more than 1200%, more preferably more than 1300%. The swelling rate of the polymer compound in water is preferably 3000% or less, more preferably 2900% or less, more preferably 2800% or less, more preferably 2700% or less, still more preferably 2600% or less. Viruses often exist in liquids containing moisture such as saliva. If the swelling rate of a polymer compound in water is more than 800%, the polymer compound will swell effectively due to contact with the liquid containing the virus and moisture, thereby increasing the surface area. By increasing the amount, it becomes a form that easily interacts with viruses, and the virus infection inhibitory effect of the virus infection inhibitor is improved. If the swelling rate of the polymer compound in water is less than 3000%, the shape change of the polymer compound during use can be reduced, the shedding of the virus infection inhibitor from the coating film can be reduced, and the excellence of the coating film can be stably maintained. Virus infection inhibitory effect.
高分子化合物於水中之膨潤率係指按下述要領所測得之值。即,稱量高分子化合物C g,將其於60℃之純化水中浸漬24小時並利用200目之金屬絲網過濾不溶解成分,於25℃放置2小時後,測定金屬絲網上之殘渣之重量(D g),藉由下式算出膨潤率。 高分子化合物於水中之膨潤率(質量%)=(D/C)×100 The swelling rate of polymer compounds in water refers to the value measured according to the following methods. That is, the polymer compound C g was weighed, immersed in purified water at 60°C for 24 hours, and the insoluble components were filtered through a 200-mesh wire mesh. After leaving it at 25°C for 2 hours, the residue on the wire mesh was measured. Weight (D g), calculate the swelling rate according to the following formula. Swelling rate of polymer compounds in water (mass %) = (D/C) × 100
病毒感染抑制劑含有高分子化合物作為有效成分,但病毒感染抑制劑之製造方法並無特別限定,可按通用之要領向高分子化合物混合視需要添加之化合物而製造病毒感染抑制劑。The viral infection inhibitor contains a polymer compound as an active ingredient, but the manufacturing method of the viral infection inhibitor is not particularly limited. The viral infection inhibitor can be produced by mixing the polymer compound with compounds added as needed according to general methods.
病毒感染抑制劑亦可附著(載持)於基底粒子之表面而使用。藉由使病毒感染抑制劑預先附著於基底粒子之表面,病毒感染抑制劑不會成為塊狀,可於塗料中均勻地分散。因此,可使病毒感染抑制劑不結塊(lump)而良好地分散於塗料中,可不於被塗敷體上產生條紋狀凹凸地形成塗敷膜,並形成表面性優異之塗膜。進而,可增大病毒感染抑制劑之表面積,可充分確保病毒感染抑制劑與病毒之接觸,充分發揮病毒感染抑制劑之病毒感染抑制效果。Viral infection inhibitors can also be attached (carried) to the surface of base particles for use. By attaching the virus infection inhibitor to the surface of the base particles in advance, the virus infection inhibitor does not become lumpy and can be evenly dispersed in the paint. Therefore, the virus infection inhibitor can be dispersed well in the paint without clumping, a coating film can be formed without stripe-like unevenness on the object to be coated, and a coating film with excellent surface properties can be formed. Furthermore, the surface area of the virus infection inhibitor can be increased, the contact between the virus infection inhibitor and the virus can be fully ensured, and the virus infection inhibitory effect of the virus infection inhibitor can be fully exerted.
作為供病毒感染抑制劑附著於表面之基底粒子,只要不阻礙病毒感染抑制劑之病毒感染抑制效果,則無特別限定。基底粒子包含樹脂粒子及無機粒子。基底粒子可單獨使用亦可將兩種以上併用。The base particles on which the viral infection inhibitor is attached to the surface are not particularly limited as long as they do not hinder the viral infection inhibitory effect of the viral infection inhibitor. Base particles include resin particles and inorganic particles. The base particles may be used alone or in combination of two or more types.
作為構成樹脂粒子之合成樹脂例如可例舉:苯乙烯系樹脂、丙烯酸系樹脂、胺酯(urethane)系樹脂、氯乙烯系樹脂、ABS樹脂;苯乙烯-丁二烯橡膠(SBR)、腈-丁二烯橡膠(NBR)等合成橡膠等,較佳為苯乙烯系樹脂及丙烯酸系樹脂。Examples of the synthetic resin constituting the resin particles include styrene resin, acrylic resin, urethane resin, vinyl chloride resin, ABS resin; styrene-butadiene rubber (SBR), nitrile- Synthetic rubber such as butadiene rubber (NBR), styrenic resin and acrylic resin are preferred.
作為苯乙烯系樹脂並無特別限定,例如可例舉:包含苯乙烯、甲基苯乙烯、乙基苯乙烯、異丙基苯乙烯、二甲基苯乙烯、氯苯乙烯、溴苯乙烯等苯乙烯系單體作為單體單元之均聚物或共聚物;包含苯乙烯系單體、及可與該苯乙烯系單體共聚之一種或兩種以上之乙烯系單體作為單體單元之共聚物等。The styrenic resin is not particularly limited, and examples thereof include benzene, such as styrene, methylstyrene, ethylstyrene, isopropylstyrene, dimethylstyrene, chlorostyrene, and bromostyrene. Homopolymers or copolymers of vinyl monomers as monomer units; copolymers including styrene monomers and one or more vinyl monomers copolymerizable with the styrene monomers as monomer units Things etc.
作為可與苯乙烯系單體共聚之乙烯系單體,例如可例舉:丙烯腈、甲基丙烯腈、丙烯酸、甲基丙烯酸、丙烯酸酯(丙烯酸甲酯、丙烯酸乙酯、丙烯酸丁酯等)、甲基丙烯酸酯(甲基丙烯酸甲酯、甲基丙烯酸乙酯、甲基丙烯酸丁酯等)等丙烯酸系單體、順丁烯二酸酐、丙烯醯胺等。Examples of vinyl monomers copolymerizable with styrene-based monomers include acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, and acrylates (methyl acrylate, ethyl acrylate, butyl acrylate, etc.) , acrylic monomers such as methacrylates (methyl methacrylate, ethyl methacrylate, butyl methacrylate, etc.), maleic anhydride, acrylamide, etc.
作為丙烯酸系樹脂並無特別限定,例如可例舉:包含(甲基)丙烯酸甲酯、(甲基)丙烯酸乙酯、(甲基)丙烯酸丁酯、(甲基)丙烯酸戊酯等丙烯酸系單體作為單體單元之均聚物或共聚物;包含丙烯酸系單體、及可與該丙烯酸系單體共聚之一種或兩種以上之乙烯系單體作為單體單元之共聚物等。再者,(甲基)丙烯酸酯意指丙烯酸酯或甲基丙烯酸酯。The acrylic resin is not particularly limited, and examples thereof include acrylic monomers such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, and amyl (meth)acrylate. Homopolymers or copolymers of monomer units; copolymers including acrylic monomers and one or more vinyl monomers that can be copolymerized with the acrylic monomers as monomer units. Furthermore, (meth)acrylate means acrylate or methacrylate.
作為可與丙烯酸系單體共聚之乙烯系單體,可例舉丙烯腈、甲基丙烯腈、順丁烯二酸酐、丙烯醯胺等。Examples of the vinyl monomer copolymerizable with the acrylic monomer include acrylonitrile, methacrylonitrile, maleic anhydride, acrylamide, and the like.
作為構成無機粒子之無機材料並無特別限定,例如可例舉沸石、水滑石、碳酸鈣、檸檬酸鈣、碳酸鎂、氫氧化鎂等。The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, and magnesium hydroxide.
構成樹脂粒子之合成樹脂較佳為含有芳香族環。芳香族環可吸引附著於樹脂粒子表面之高分子化合物之疏水性部分,發揮使羧基朝外側配向之作用,更有效地發揮病毒感染抑制劑之病毒感染抑制效果。The synthetic resin constituting the resin particles preferably contains an aromatic ring. The aromatic ring can attract the hydrophobic part of the polymer compound attached to the surface of the resin particles, and play a role in orienting the carboxyl groups toward the outside, thereby more effectively exerting the virus infection inhibitory effect of the virus infection inhibitor.
芳香族環可為單環狀之芳香族環,亦可單環狀之芳香族環複合並縮合而成(縮合芳香族環)。芳香族環並無特別限定,例如可例舉苯環、萘環、蒽環、聯苯、苯氧基苯基等。芳香族環中,鍵結於直接構成芳香族環及縮合芳香族環之碳原子之氫原子中之任一個或複數個氫原子被奪去,並藉由共價鍵與其他原子鍵結。The aromatic ring can be a monocyclic aromatic ring, or it can be formed by compounding and condensing monocyclic aromatic rings (condensed aromatic ring). The aromatic ring is not particularly limited, and examples thereof include benzene ring, naphthalene ring, anthracene ring, biphenyl, phenoxyphenyl group, and the like. In an aromatic ring, any one or more of the hydrogen atoms bonded to the carbon atoms directly constituting the aromatic ring and the condensed aromatic ring are taken away and bonded to other atoms through covalent bonds.
高分子化合物對基底粒子之附著量較佳為相對於基底粒子100質量份為1質量份以上,更佳為5質量份以上,更佳為7質量份以上,更佳為10質量份以上。若高分子化合物之附著量為1質量份以上,則可使病毒感染抑制劑均勻地附著於基底粒子之表面,可更有效地發揮病毒感染抑制劑之病毒感染抑制效果。The adhesion amount of the polymer compound to the base particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more based on 100 parts by mass of the base particles. If the adhesion amount of the polymer compound is 1 part by mass or more, the virus infection inhibitor can be uniformly attached to the surface of the base particles, and the virus infection inhibitory effect of the virus infection inhibitor can be more effectively exerted.
高分子化合物對基底粒子之附著量較佳為相對於基底粒子100質量份為50質量份以下,更佳為40質量份以下,更佳為30質量份以下,更佳為20質量份以下。若高分子化合物之附著量為50質量份以下,則病毒感染抑制劑不會彼此鍵結,病毒感染抑制劑有效率地配置於樹脂粒子表面,病毒感染抑制效果提高。The adhesion amount of the polymer compound to the base particles is preferably 50 parts by mass or less, more preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less based on 100 parts by mass of the base particles. If the adhesion amount of the polymer compound is 50 parts by mass or less, the virus infection inhibitors will not be bonded to each other, the virus infection inhibitors will be efficiently arranged on the surface of the resin particles, and the virus infection inhibitory effect will be improved.
病毒感染抑制劑附著於基底粒子表面之要領並無特別限定,例如可藉由病毒感染抑制劑之接著力來附著,亦可使用黏合劑樹脂使病毒感染抑制劑接著於基底粒子之表面,較佳為高分子化合物藉由高分子化合物本身之接著力而附著於基底粒子之表面,原因在於可有效地發揮病毒感染抑制劑之病毒感染抑制效果。The method of adhering the virus infection inhibitor to the surface of the base particles is not particularly limited. For example, it can be attached by the adhesion force of the virus infection inhibitor, or an adhesive resin can be used to adhere the virus infection inhibitor to the surface of the base particle. Preferably The polymer compound is attached to the surface of the base particles through the adhesive force of the polymer compound itself. The reason is that it can effectively exert the virus infection inhibitory effect of the virus infection inhibitor.
病毒感染抑制劑因高分子化合物之作用而對各種病毒具有病毒感染抑制效果,對套膜病毒及無套膜病毒兩者均發揮優異之病毒感染抑制效果。Viral infection inhibitors have viral infection inhibitory effects on various viruses due to the action of polymer compounds, and exhibit excellent viral infection inhibitory effects on both mantle viruses and non-mantle viruses.
作為套膜病毒例如可例舉:流感病毒(例如A型、B型等)、風疹病毒、伊波拉病毒、冠狀病毒[例如SARS病毒、新型冠狀病毒(SARS-CoV-2)]、麻疹病毒、水痘-帶狀疱疹病毒、單純疱疹病毒、腮腺炎病毒、節肢足動物攜帶性病毒、RS病毒、肝炎病毒(例如B型肝炎病毒、C型肝炎病毒等)、黃熱病毒、愛滋病毒、狂犬病病毒、漢他病毒、登革熱病毒、立百病毒(Nipah virus)、麗莎病毒等。Examples of the mantle virus include influenza virus (such as type A, type B, etc.), rubella virus, Ebola virus, coronavirus (such as SARS virus, novel coronavirus (SARS-CoV-2)), measles virus, Varicella-zoster virus, herpes simplex virus, mumps virus, arthropod-borne virus, RS virus, hepatitis virus (such as hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, HIV, rabies Viruses, hantavirus, dengue virus, Nipah virus, Lisa virus, etc.
作為無套膜病毒例如可例舉:貓杯狀病毒、腺病毒、諾羅病毒、輪狀病毒、人類乳突病毒、脊髓灰白質炎病毒、腸病毒、柯薩奇病毒、人類小病毒、腦心肌炎病毒、鼻病毒等。Examples of non-enveloped viruses include: feline calicivirus, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, cerebral parvovirus, Myocarditis virus, rhinovirus, etc.
藉由使病毒感染抑制劑包含於塗料中而構成病毒感染抑制塗料。由病毒感染抑制塗料形成之塗膜發揮優異之病毒感染抑制效果。The viral infection inhibitory paint is included in the paint to form a virus infection-inhibiting paint. The coating film formed by the virus infection-inhibiting paint exhibits excellent virus infection-inhibiting effects.
病毒感染抑制塗料中之高分子化合物之含量較佳為1質量%以上,更佳為2質量%以上。病毒感染抑制塗料中之高分子化合物之含量較佳為10質量%以下,更佳為7質量%以下,更佳為5質量%以下。若高分子化合物之含量為1質量%以上,則由病毒感染抑制塗料形成之塗膜發揮優異之病毒感染抑制效果。若高分子化合物之含量為10質量%以下,則由病毒感染抑制塗料形成之塗膜之表面性提升。The content of the polymer compound in the virus infection inhibiting paint is preferably 1% by mass or more, more preferably 2% by mass or more. The content of the polymer compound in the virus infection-inhibiting paint is preferably 10 mass% or less, more preferably 7 mass% or less, and more preferably 5 mass% or less. If the content of the polymer compound is 1% by mass or more, the coating film formed of the virus infection-inhibiting paint exhibits an excellent virus infection-inhibiting effect. If the content of the polymer compound is 10% by mass or less, the surface properties of the coating film formed by the virus infection-inhibiting paint will be improved.
病毒感染抑制劑如上所述,藉由使高分子化合物具有交聯結構,而使得塗料之吸收減少,從而於塗料中良好地分散,藉由將含有該病毒感染抑制劑之病毒感染抑制塗料塗敷於被塗敷體上,可形成沒有條紋等凹凸之表面性優異之塗敷膜。藉由使該塗敷膜乾燥並視需要使其硬化,可獲得沒有條紋等凹凸之表面性(外觀)優異之塗膜。As mentioned above, the viral infection inhibitor has a cross-linked structure in the polymer compound, which reduces the absorption of the paint and is well dispersed in the paint. By applying the viral infection inhibitory paint containing the virus infection inhibitor It can form a coating film with excellent surface properties without unevenness such as streaks on the object to be coated. By drying the coating film and hardening it if necessary, a coating film having excellent surface properties (appearance) without irregularities such as streaks can be obtained.
再者,作為塗敷病毒感染抑制塗料之被塗敷體,只要為欲賦予病毒感染抑制效果者,則無特別限定,例如可例舉:合成樹脂成形體、壁紙、裝飾板、地板材、纖維製品(織物、不織物、針織物)、交通工具(例如車、飛機、船等)用內部用品及內裝材(座椅、兒童座椅及構成其等之發泡體等)、廚房用品、嬰兒用品、建築內裝材等。Furthermore, there is no particular limitation on the object to be coated with the viral infection-inhibiting paint, as long as it is intended to impart a virus infection-inhibiting effect. Examples thereof include: synthetic resin molded articles, wallpapers, decorative boards, flooring materials, and fibers. Products (fabrics, non-woven fabrics, knitted fabrics), interior products and interior materials for vehicles (such as cars, airplanes, ships, etc.) (seats, child seats and foams constituting them, etc.), kitchen supplies, Baby products, building interior materials, etc.
建築內裝材並無特別限定,例如可例舉:地板材、壁紙、天花板材、塗料、門把手、開關、開關罩、蠟等。Building interior materials are not particularly limited, and examples thereof include: floor materials, wallpaper, ceiling materials, paint, door handles, switches, switch covers, wax, etc.
交通工具內部用品及交通工具內裝材並無特別限定,例如可例舉:座椅、兒童座椅、安全帶、汽車腳墊、座椅套、車門、天花板材、地毯、門飾板、儀錶面板、控制台、副駕駛座置物箱、吊環、扶手等。Vehicle interior supplies and vehicle interior materials are not particularly limited. Examples include: seats, child seats, seat belts, car floor mats, seat covers, doors, ceiling materials, carpets, door trims, and instruments. Panels, consoles, passenger seat storage boxes, lifting rings, armrests, etc.
作為塗料,使用以往公知之塗料。塗料較佳為疏水性塗料,原因在於病毒感染抑制劑之分散性提高,可形成表面性優異之塗膜。疏水性塗料並無特別限定,例如可例舉:油性塗料(例如調合漆、油性清漆等)、纖維素塗料、合成樹脂塗料等。塗料亦包含藉由紫外線等放射線之照射進行聚合而生成黏合劑成分之光硬化性塗料。As the paint, a conventionally known paint is used. The coating is preferably a hydrophobic coating because the dispersibility of the virus infection inhibitor is improved and a coating film with excellent surface properties can be formed. The hydrophobic paint is not particularly limited, and examples thereof include oily paints (such as mixed paints, oily varnishes, etc.), cellulose paints, and synthetic resin paints. Coatings also include photocurable coatings that are polymerized by irradiation with ultraviolet rays and other radiation to produce a binder component.
為了調整黏度,塗料亦可含有溶劑。作為溶劑,較佳為有機溶劑,原因在於病毒感染抑制劑於塗料中之分散性提高。作為有機溶劑並無特別限定,例如可例舉:甲苯、二甲苯、甲基乙基酮、丙酮、乙酸乙酯、苯等。再者,溶劑可單獨使用亦可將兩種以上併用。To adjust the viscosity, the coating may also contain solvents. As the solvent, an organic solvent is preferred because the dispersibility of the virus infection inhibitor in the paint is improved. The organic solvent is not particularly limited, and examples thereof include toluene, xylene, methyl ethyl ketone, acetone, ethyl acetate, benzene, and the like. In addition, a solvent may be used individually or in combination of 2 or more types.
進而,塗料亦可於無損其物性之範圍內含有顏料、塑化劑、硬化劑、增量劑、填充劑、防老化劑、增黏劑、界面活性劑等添加劑。Furthermore, the coating may also contain additives such as pigments, plasticizers, hardeners, extenders, fillers, anti-aging agents, tackifiers, and surfactants within the range that does not impair its physical properties.
作為使塗料中含有病毒感染抑制劑之方法,例如可例舉將病毒感染抑制劑及塗料供給至分散裝置而均勻地混合之方法等。再者,作為分散裝置例如可例舉高速研磨機、球磨機、砂磨機等。 [實施例] An example of a method for containing a virus infection inhibitor in the coating material is a method of supplying the virus infection inhibitor and the coating material to a dispersing device and mixing them uniformly. Examples of the dispersing device include a high-speed grinder, a ball mill, and a sand mill. [Example]
以下,使用實施例更具體地對本發明進行說明,但本發明並不限定於此。Hereinafter, the present invention will be described more specifically using examples, but the present invention is not limited thereto.
準備含羧基之高分子化合物1~13作為高分子化合物,將該等高分子化合物用作病毒感染抑制劑。Carboxyl group-containing polymer compounds 1 to 13 were prepared as polymer compounds, and these polymer compounds were used as viral infection inhibitors.
・含羧基之高分子化合物1(具有交聯結構之聚丙烯酸、FUJIFILM Wako Pure Chemical公司製造 商品名「HIVISWAKO 103」) ・含羧基之高分子化合物2(具有交聯結構之聚丙烯酸、住友精化公司製造 商品名「HV-803ERK」) ・含羧基之高分子化合物3(具有交聯結構之聚丙烯酸、住友精化公司製造 商品名「SW-705ER」) ・含羧基之高分子化合物4(具有交聯結構之聚丙烯酸、東亞合成公司製造 商品名「PW-120」) ・含羧基之高分子化合物5(具有交聯結構之聚丙烯酸、住友精化公司製造 商品名「SW-703ER」) ・含羧基之高分子化合物6(具有交聯結構之聚丙烯酸、FUJIFILM Wako Pure Chemical公司製造 商品名「HIVISWAKO 104」) ・含羧基之高分子化合物7(具有交聯結構之聚丙烯酸、Nippon Surfactant Industries公司製造 商品名「NTC-CARBOMER 381」) ・含羧基之高分子化合物8(具有交聯結構之聚丙烯酸、Nippon Surfactant Industries公司製造 商品名「NTC-CARBOMER 380」) ・含羧基之高分子化合物9(具有交聯結構之聚丙烯酸、住友精化公司製造 商品名「SW-705E」) ・含羧基之高分子化合物10(具有交聯結構之聚丙烯酸、FUJIFILM Wako Pure Chemical公司製造 商品名「HIVISWAKO 105」) ・含羧基之高分子化合物11(聚丙烯酸、日本觸媒公司製造 商品名「AS-58」) ・含羧基之高分子化合物12(聚丙烯酸、FUJIFILM Wako Pure Chemical公司製造 商品名「Polyacrylic Acid 250,000」) ・含羧基之高分子化合物13(聚丙烯酸、東亞合成公司製造 商品名「AC-10P」) ・Carboxyl group-containing polymer compound 1 (polyacrylic acid with a cross-linked structure, manufactured by FUJIFILM Wako Pure Chemical Co., Ltd., trade name "HIVISWAKO 103") ・Carboxyl group-containing polymer compound 2 (polyacrylic acid with a cross-linked structure, manufactured by Sumitomo Seika Co., Ltd., trade name "HV-803ERK") ・Carboxyl group-containing polymer compound 3 (polyacrylic acid with a cross-linked structure, manufactured by Sumitomo Seika Co., Ltd., trade name "SW-705ER") ・Carboxyl group-containing polymer compound 4 (polyacrylic acid with a cross-linked structure, manufactured by Toagosei Co., Ltd., trade name "PW-120") ・Carboxyl group-containing polymer compound 5 (polyacrylic acid with a cross-linked structure, manufactured by Sumitomo Seika Co., Ltd., trade name "SW-703ER") ・Carboxyl group-containing polymer compound 6 (polyacrylic acid with a cross-linked structure, manufactured by FUJIFILM Wako Pure Chemical Co., Ltd., trade name "HIVISWAKO 104") ・Carboxyl group-containing polymer compound 7 (polyacrylic acid with a cross-linked structure, manufactured by Nippon Surfactant Industries, trade name "NTC-CARBOMER 381") ・Carboxyl group-containing polymer compound 8 (polyacrylic acid with a cross-linked structure, manufactured by Nippon Surfactant Industries, trade name "NTC-CARBOMER 380") ・Carboxyl group-containing polymer compound 9 (polyacrylic acid with a cross-linked structure, manufactured by Sumitomo Seika Co., Ltd., trade name "SW-705E") ・Carboxyl group-containing polymer compound 10 (polyacrylic acid with a cross-linked structure, manufactured by FUJIFILM Wako Pure Chemical Co., Ltd., trade name "HIVISWAKO 105") ・Carboxyl group-containing polymer compound 11 (polyacrylic acid, manufactured by Nippon Shokubai Co., Ltd., trade name "AS-58") ・Carboxyl group-containing polymer compound 12 (polyacrylic acid, manufactured by FUJIFILM Wako Pure Chemical Co., Ltd., trade name "Polyacrylic Acid 250,000") ・Carboxyl group-containing polymer compound 13 (polyacrylic acid, manufactured by Toagosei Co., Ltd., trade name "AC-10P")
[含羧基之高分子化合物1~13之粒子之製作] 使用輥壓裝置(Seishin Enterprise公司 商品名「150型」)於轉速25 rpm、擠壓力25 t之運轉條件下將含羧基之高分子化合物粗粉碎後,使用噴射磨機裝置(Nisshin Engineering公司製造 商品名「SJ-500」),於含羧基之高分子化合物之供給速度1 kg/h、壓縮空氣壓力0.75 MPa之運轉條件下進行粉碎而獲得含羧基之高分子化合物粒子。 [Preparation of particles of carboxyl group-containing polymer compounds 1 to 13] The carboxyl group-containing polymer compound was coarsely pulverized using a roller press (trade name "Model 150" manufactured by Seishin Enterprise Co., Ltd.) under operating conditions of rotation speed 25 rpm and extrusion force 25 t, and then a jet mill device (manufactured by Nisshin Engineering Co., Ltd. Trade name "SJ-500"), the carboxyl group-containing polymer compound particles are pulverized under operating conditions of a supply rate of 1 kg/h and a compressed air pressure of 0.75 MPa to obtain carboxyl group-containing polymer compound particles.
[粒子附著含羧基之高分子化合物8之製作] 將含羧基之高分子化合物8之粒子0.05質量份、及具有平均粒徑4 μm之聚苯乙烯粒子(一次粒子)0.1質量份供給至水100質量份,使用噴霧乾燥器以霧化器旋轉速度20000 rpm進行粉體化,使含羧基之高分子化合物8之所有粒子附著(載持)於聚苯乙烯粒子之表面,其後使用噴射磨機裝置(Nisshin Engineering公司製造商品名「SJ-500」),於原料供給速度1 kg/h、壓縮空氣壓力0.75 MPa之運轉條件下進行粉碎,獲得表面附著有含羧基之高分子化合物8之粒子之聚苯乙烯粒子。再者,於表1中,將「表面附著有含羧基之高分子化合物8之粒子之聚苯乙烯粒子」記為「粒子附著含羧基之高分子化合物8」。 [Preparation of polymer compound 8 containing carboxyl groups attached to particles] 0.05 parts by mass of particles of carboxyl group-containing polymer compound 8 and 0.1 part by mass of polystyrene particles (primary particles) having an average particle diameter of 4 μm were supplied to 100 parts by mass of water, and a spray dryer was used at an atomizer rotation speed Powder was carried out at 20,000 rpm, and all the particles of the carboxyl group-containing polymer compound 8 were attached (supported) to the surface of the polystyrene particles, and then a jet mill device (trade name "SJ-500" manufactured by Nisshin Engineering Co., Ltd. ), pulverized under operating conditions of raw material supply rate 1 kg/h and compressed air pressure 0.75 MPa to obtain polystyrene particles with particles of carboxyl group-containing polymer compound 8 attached to the surface. In addition, in Table 1, "polystyrene particles with particles of the carboxyl group-containing polymer compound 8 attached to the surface" are described as "particles with the carboxyl group-containing polymer compound 8 attached."
對實施例及比較例中所使用之含羧基之高分子化合物,將重量平均分子量Mw、pKa1、於25℃之pH[pH(25℃)]、羧基及羧基之鹽之總含量、於水中之膨潤率、及凝膠分率示於表1。再者,於表1中,「於水中之膨潤率」簡寫為「膨潤率」。再者,由於含羧基之高分子化合物1~10具有交聯結構,因此無法測定重量平均分子量Mw。For the carboxyl group-containing polymer compounds used in the examples and comparative examples, the weight average molecular weight Mw, pKa1, pH at 25°C [pH (25°C)], the total content of the carboxyl group and the salt of the carboxyl group, and the The swelling rate and gel fraction are shown in Table 1. Furthermore, in Table 1, "swelling rate in water" is abbreviated as "swelling rate". Furthermore, since the carboxyl group-containing polymer compounds 1 to 10 have a cross-linked structure, the weight average molecular weight Mw cannot be measured.
(實施例1~11及比較例1~3) 將包含按上述要領所製作之「表1所示之含羧基之高分子化合物粒子」3質量份的病毒感染抑制劑、及紫外線硬化型丙烯酸系塗料(COATTEC公司製造 商品名「AI-N2」)97質量份混合而製作病毒感染抑制塗料。使用線棒塗佈器#8,將病毒感染抑制塗料於聚乙烯膜上塗敷成厚度18 μm而形成塗敷層。再者,於實施例11中,調整為含羧基之高分子化合物8之粒子達到3質量份。 (Examples 1 to 11 and Comparative Examples 1 to 3) A viral infection inhibitor containing 3 parts by mass of the "carboxyl group-containing polymer compound particles shown in Table 1" produced according to the above method, and an ultraviolet curable acrylic paint (trade name "AI-N2" manufactured by COATTEC) 97 parts by mass were mixed to prepare a virus infection inhibiting paint. Using wire bar applicator #8, apply the viral infection-inhibiting paint on the polyethylene film to a thickness of 18 μm to form a coating layer. Furthermore, in Example 11, the particles of the carboxyl group-containing polymer compound 8 were adjusted to 3 parts by mass.
使用UV輸送裝置(EYE GRAPHICS公司製造之「ECS301G1」),於25℃向塗敷層照射波長365 nm之紫外線直至累計光量達到500 mJ/cm 2,使紫外線硬化型丙烯酸系塗料硬化,而形成厚度為18 μm之塗膜。 Using a UV delivery device ("ECS301G1" manufactured by EYE GRAPHICS), the coating layer is irradiated with ultraviolet rays of wavelength 365 nm at 25°C until the cumulative light intensity reaches 500 mJ/cm 2 to harden the ultraviolet curable acrylic paint to form a thickness It is an 18 μm coating.
對病毒感染抑制劑按下述要領測定抗病毒性及分散性,將其結果示於表1。The antiviral properties and dispersibility of the viral infection inhibitors were measured according to the following method, and the results are shown in Table 1.
[抗病毒性] 使用上文所獲得之塗膜,使用流感病毒(套膜病毒)及貓杯狀病毒(無套膜病毒)按下述要領進行抗病毒試驗。 [Antiviral properties] Using the coating film obtained above, antiviral tests were conducted using influenza virus (mantle virus) and feline calicivirus (non-mantle virus) according to the following methods.
(抗病毒試驗) 對塗膜切出一邊為5.0 cm之平面正方形狀,藉此製作試片。 (Antiviral test) Cut out a flat square shape with a side of 5.0 cm from the coating film to make a test piece.
對所獲得之試片塗膜之表面,使用一邊為10 cm之平面正方形狀之不織布(NIPPON PAPER CRECIA公司製造 商品名「Kimwipe S-200」),使不織布往返10次以進行擦拭,而製成試驗塗膜。The surface of the coating film of the obtained test piece was wiped with a flat square-shaped non-woven fabric (trade name "Kimwipe S-200" manufactured by NIPPON PAPER CRECIA Co., Ltd.) with a side of 10 cm, and the non-woven fabric was wiped back and forth 10 times to prepare it. Test coating.
對所獲得之試驗塗膜,依據ISO21702進行流感病毒及貓杯狀病毒之抗病毒試驗。對反應後之病毒懸濁液,藉由溶菌斑法算出試驗塗膜之病毒感染效價。The obtained test coating was subjected to antiviral tests for influenza virus and feline calicivirus according to ISO21702. For the virus suspension after the reaction, the virus infection titer of the test coating was calculated by the plaque lysis method.
除不含有病毒感染抑制劑以外,按與上文相同之要領製作空白塗膜,基於該空白塗膜,按與上文相同之要領算出病毒感染效價(常用對數值)(PFU/cm 2)。空白塗膜之病毒感染效價(常用對數值)為6.5 PFU/cm 2。 Except that it does not contain viral infection inhibitors, make a blank coating film according to the same method as above. Based on the blank coating film, calculate the viral infection titer (common logarithmic value) (PFU/cm 2 ) according to the same method as above. . The virus infection titer (commonly used logarithmic value) of the blank coating film is 6.5 PFU/cm 2 .
自空白塗膜之病毒感染效價減去試驗塗膜之病毒感染效價,藉此算出抗病毒活性值。The antiviral activity value was calculated by subtracting the viral infection titer of the test coating from the viral infection titer of the blank coating.
[分散性] 對所獲得之病毒感染抑制塗料,依據JIS K5600-2-5,使用研磨規(grind gage)觀察開始出現斑點之位置。 [Dispersion] The obtained virus infection-inhibiting paint was observed using a grind gauge in accordance with JIS K5600-2-5 to observe the position where spots began to appear.
[表1]
本發明之病毒感染抑制劑含有於塗料中之情形時,可發揮優異之分散性,良好地分散至塗料中。因此,將包含本發明之病毒感染抑制劑之塗料塗敷於被塗敷體上而獲得之塗敷膜具有優異之表面性,使該塗敷膜乾燥而獲得之塗膜具有優異之外觀性。When the viral infection inhibitor of the present invention is contained in a paint, it exhibits excellent dispersibility and is well dispersed into the paint. Therefore, a coating film containing the viral infection inhibitor of the present invention is applied to an object to be coated, and the coating film obtained has excellent surface properties, and the coating film obtained by drying the coating film has excellent appearance properties.
(相關申請案之相互參照) 本申請案主張基於2022年3月10日提出申請之日本特許申請第2022-037394號之優先權,該申請案之內容以參照之方式將其整體併入至本說明書中。 (Cross-reference of related applications) This application claims priority based on Japanese Patent Application No. 2022-037394 filed on March 10, 2022, the contents of which are incorporated into this specification in its entirety by reference.
無without
無without
Claims (9)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022-037394 | 2022-03-10 | ||
JP2022037394 | 2022-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202348136A true TW202348136A (en) | 2023-12-16 |
Family
ID=87935337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW112108497A TW202348136A (en) | 2022-03-10 | 2023-03-08 | Viral infection inhibitor, viral infection-inhibiting particles, and viral infection-inhibiting paint |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202348136A (en) |
WO (1) | WO2023171555A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5820112B2 (en) * | 2010-12-15 | 2015-11-24 | 積水化学工業株式会社 | Influenza virus infection inhibitor, influenza virus infection prevention paint and influenza virus infection prevention product |
JP5979577B2 (en) * | 2012-01-23 | 2016-08-24 | 日本エクスラン工業株式会社 | Anti-influenza virus particles and anti-influenza virus products containing the particles |
RU2517142C2 (en) * | 2012-04-27 | 2014-05-27 | Общество с ограниченной ответственностью "Инновационные полимерные адгезивы" | Hydrophilic pressure-sensitive bioadhesive with targeted adhesion towards teeth and dental care composition based thereon |
JP6155109B2 (en) * | 2012-12-19 | 2017-06-28 | 積水化成品工業株式会社 | Crosslinked polymer and method for producing the same |
WO2018235816A1 (en) * | 2017-06-21 | 2018-12-27 | 中国塗料株式会社 | Photocurable resin composition, cured coating film, substrate with cured coating film, method for producing same, and virus inactivation method |
WO2020203069A1 (en) * | 2019-04-04 | 2020-10-08 | リケンテクノス株式会社 | Paint for formation of antiviral coating film, coating film, and laminated film |
-
2023
- 2023-03-03 WO PCT/JP2023/007987 patent/WO2023171555A1/en active Application Filing
- 2023-03-08 TW TW112108497A patent/TW202348136A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023171555A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6424211B2 (en) | Multilayer pressure sensitive adhesive assembly | |
Wang et al. | Surface modification of hydroxyapatite with poly (methyl methacrylate) via surface-initiated ATRP | |
JP7406679B2 (en) | Virus infection inhibitors and virus infection prevention products | |
ES2362642T3 (en) | ADHESIVE MASSES AND PROCEDURES FOR MANUFACTURING. | |
KR20080040011A (en) | Emulsion for vibration damper | |
JP2024001067A (en) | Laminate, optical member and optical device | |
BR112015031262B1 (en) | use of a 2-octyl acrylate polymer as a bonding agent in a coating composition | |
JP5620320B2 (en) | Adhesive laminate | |
TW202348136A (en) | Viral infection inhibitor, viral infection-inhibiting particles, and viral infection-inhibiting paint | |
JP2023142828A (en) | Viral infection inhibitor, viral infection inhibitory particle, and viral infection inhibitory coating | |
JPH11209523A (en) | Chloroprene latex composition and adhesive composition | |
JPH02140272A (en) | Crosslinked hollow polymer pigment and coating composition using the pigment | |
CN117042606A (en) | Virus infection suppressing particles and virus infection suppressing product | |
TW202348138A (en) | Viral infection inhibitor, viral infection inhibiting member, and viral infection inhibiting paint | |
JP5881496B2 (en) | Undercoat for release substrate | |
JP2023067367A (en) | Viral infection inhibitor and product for inhibiting viral infection | |
TW202348139A (en) | Viral infection-inhibiting member | |
BR102013015790A2 (en) | Homogeneous or structured synthesis procedure for obtaining an anticorrosive polymer resin, anticorrosive polymer resin and use thereof | |
TW202425810A (en) | Virus infection inhibitor, resin composition, masterbatch for synthetic resin molding, and virus infection inhibitor product | |
TW202417060A (en) | Viral infection inhibitory agent, resin composition, and viral infection inhibitory product | |
WO2024043320A1 (en) | Viral infection inhibitor, viral infection inhibition product, and method for manufacturing viral infection inhibition product | |
WO2024053654A1 (en) | Viral infection inhibitor, resin composition, masterbatch for synthetic resin molding, and viral infection inhibition product | |
TW202325270A (en) | Viral infection inhibitor and viral infection inhibitory product | |
JPH02140271A (en) | Hollow polymer pigment and coating composition using the pigment | |
CN118201494A (en) | Viral infection inhibitor and viral infection inhibitor product |